Literature DB >> 29741149

Case Report: Probable Case of Spontaneous Encephalopathy Due to Loiasis and Dramatic Reduction of Loa loa Microfilariaemia with Prolonged Repeated Courses of Albendazole.

Divine B Arrey-Agbor1, Hugues C Nana-Djeunga2,1, Aude E Mogoung-Wafo1, Mirabelle Mafo1, Christian Danwe3, Joseph Kamgno1,4.   

Abstract

Loiasis is a vector-borne parasitic disease caused by the filarial nematode Loa loa and transmitted by the tabanid vectors from the genus Chrysops. Loa loa infection is associated with clinical manifestations such as pruritus, migratory transient edema, passage of adult worm in the bulbar conjunctiva, retinal damage, glomerular damage, albuminuria, pleural effusion, hydrocele, and endomyocardial fibrosis. Data reporting the occurrence of spontaneous encephalopathy associated with loiasis are very scanty. Severe adverse events occurring post-ivermectin administered in the framework of the fight against onchocerciasis and/or lymphatic filariasis in loiasis co-endemic areas have been closely associated with very high L. loa microfilariaemia. Different regimens have been used to lower L. loa microfilariaemia before definitive treatment, and many discrepancies have been reported. We report the case of a patient who was admitted to a health facility and hospitalized for 34 days for altered consciousness, blurred vision, headache, and chills. After other potential diagnoses were eliminated, the patient was confirmed with encephalopathy due to loiasis and referred to the Centre for Research on Filariasis and other Tropical Diseases (CRFilMT). On admission at CRFilMT, the patient was harboring 28,700 microfilariae per milliliter of blood (mf/mL), and after four 21-day courses of 400 mg daily albendazole, the L. loa microfilariaemia lowered to 5,060 mf/mL. The patient was then treated with ivermectin 3 mg and a total clearance of microfilariae was observed, with satisfactory clinical evolution and no adverse event. This case study further confirmed that albendazole is effective against L. loa, but might necessitate a longer course.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29741149      PMCID: PMC6085801          DOI: 10.4269/ajtmh.17-0664

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  32 in total

1.  Encephalitis in loa-loa filariasis.

Authors:  L VAN BOGAERT; A DUBOIS; P G JANSSENS; J RADERMECKER; G TVERDY; M WANSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1955-05       Impact factor: 10.154

2.  Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation.

Authors:  A D Klion; A Massougbodji; B C Sadeler; E A Ottesen; T B Nutman
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

3.  [Four cases of fatal encephalitis with invasion of the cerebrospinal fluid by Microfilaria loa].

Authors:  M KIVITS
Journal:  Ann Soc Belg Med Trop (1920)       Date:  1952-06

4.  Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events.

Authors:  Joseph Kamgno; Sébastien D Pion; Charles D Mackenzie; Björn Thylefors; Michel Boussinesq
Journal:  Am J Trop Med Hyg       Date:  2009-12       Impact factor: 2.345

Review 5.  Cerebral malaria.

Authors:  Douglas G Postels; Gretchen L Birbeck
Journal:  Handb Clin Neurol       Date:  2013

6.  Relationships between the prevalence and intensity of Loa loa infection in the Central province of Cameroon.

Authors:  M Boussinesq; J Gardon; J Kamgno; S D Pion; N Gardon-Wendel; J P Chippaux
Journal:  Ann Trop Med Parasitol       Date:  2001-07

7.  Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia.

Authors:  J Kamgno; M Boussinesq
Journal:  Parasite       Date:  2002-03       Impact factor: 3.000

8.  Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen.

Authors:  Tabe-Ebob Tabi; Rosa Befidi-Mengue; Thomas B Nutman; John Horton; Alain Folefack; Edith Pensia; Rellinds Fualem; Josephine Fogako; Philomene Gwanmesia; Isabella Quakyi; Rose Leke
Journal:  Am J Trop Med Hyg       Date:  2004-08       Impact factor: 2.345

9.  Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial.

Authors:  Joseph Kamgno; Patrick Nguipdop-Djomo; Raceline Gounoue; Mathurin Téjiokem; Annette C Kuesel
Journal:  PLoS Negl Trop Dis       Date:  2016-03-11

10.  Filarial antigenemia and Loa loa night blood microfilaremia in an area without bancroftian filariasis in the Democratic Republic of Congo.

Authors:  Didier K Bakajika; Maurice M Nigo; Jean Pierre Lotsima; Germain A Masikini; Kerstin Fischer; Melanie M Lloyd; Gary J Weil; Peter U Fischer
Journal:  Am J Trop Med Hyg       Date:  2014-09-15       Impact factor: 2.345

View more
  1 in total

1.  Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update.

Authors:  Jong-Yil Chai; Bong-Kwang Jung; Sung-Jong Hong
Journal:  Korean J Parasitol       Date:  2021-06-21       Impact factor: 1.341

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.